VX-950 and Peginterferon for Hepatitis C

Vertex Pharmaceuticals

Status and phase: Completed; Phase 1

Conditions: Hepatitis C

Treatments: Drug: VX-950; Drug: peginterferon

Study type: Interventional

Funder types: Industry

Identifiers

NCT00251199

VX05-950-103

Details and patient eligibility

About

VX-950 is an investigational drug , which is being tested in combination with a known treatment for hepatitis C, peginterferon.

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• infected with Hepatitis C virus

Exclusion criteria

• contraindications to peginterferon therapy